Modeling the axial extension of a transmission line source within iterative reconstruction via multiple transmission sources.

Reconstruction algorithms for transmission tomography have generally assumed that the photons reaching a particular detector bin at a particular angle originate from a single point source. In this paper, we highlight several cases of extended transmission sources, in which it may be useful to approach the estimation of attenuation coefficients as a problem involving multiple transmission point sources. Examined in detail is the case of a fixed transmission line source with a fan-beam collimator. This geometry can result in attenuation images that have significant axial blur. Herein it is also shown, empirically, that extended transmission sources can result in biased estimates of the average attenuation, and an explanation is proposed. The finite axial resolution of the transmission line source configuration is modeled within iterative reconstruction using an expectation-maximization algorithm that was previously derived for estimating attenuation coefficients from single photon emission computed tomography (SPECT) emission data. The same algorithm is applicable to both problems because both can be thought of as involving multiple transmission sources. It is shown that modeling axial blur within reconstruction removes the bias in the average estimated attenuation and substantially improves the axial resolution of attenuation images.

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

PURPOSE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgically created resection cavities (SCRCs). METHODS AND MATERIALS: Absorbed doses to the 2-cm-thick shell as measured from the margins of the resection cavity interface were estimated for 42 patients with primary brain tumors. MR images were used to assess the enhanced-rim volume as a function of time after radiolabeled MAb therapy. Biopsy samples were obtained from 15 patients and 1 autopsy. RESULTS: The average absorbed dose [range] to the 2-cm shell region was 32 [3-59] Gy. For the endpoint of minimal time to MR contrast enhancement, the optimal absorbed dose and initial dose-rate were 43 +/- 16 Gy and 0. 41 +/- 0.10 Gy/h, respectively. There was a correlation between the absorbed dose and dose rate to the shell region and biopsy outcome (tumor recurrence, radionecrosis, and tumor recurrence and/or radionecrosis). In this Phase I study, the maximum tolerated dose (MTD) was 120 mCi. At this MTD, the estimated average absorbed dose and initial dose rate to the 2-cm shell were 41 [9-89] Gy and 0.51 [0.24-1.13] Gy/h, respectively. These values are in agreement with the optimal values based on the time to MR lesion rim enhancement. CONCLUSIONS: The average absorbed dose to the 2-cm shell region varied considerably and mainly depended on cavity volume. In future clinical trials, the administered activity of (131)I-labeled 81C6 MAb may be adjusted based on cavity volume in order to deliver the optimal absorbed dose of 43 Gy rather than giving a fixed administered activity.